Theresa Sohn, MD
Allergy & Immunology · Wayne, NJNPI 1801835467
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,602, 3.7 times the $427 reported in 2019.
Across 337 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$756
- GSK$618
- Optinose US, Inc.$582
- CSL Behring$325
- Kaleo, Inc.$254
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,51599%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 71 | $1,203 |
| Regeneron Healthcare Solutions, Inc. | 47 | $756 |
| GSK | 43 | $618 |
| Optinose US, Inc. | 38 | $582 |
| CSL Behring | 18 | $325 |
| Kaleo, Inc. | 17 | $254 |
| Amgen | 13 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $200 |
| AstraZeneca | 10 | $151 |
| Biocryst US Sales Co., LLC | 8 | $136 |
| Alk-abello, Inc | 9 | $133 |
| Stryker | 3 | $125 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $100 |
| Pfizer | 4 | $61 |
| Inspire Medical Systems, Inc. | 2 | $61 |
| Organon | 3 | $54 |
| Aerin Medical Inc. | 2 | $48 |
| Hikma Pharmaceuticals USA | 3 | $47 |
| LEO Pharma Inc. | 3 | $45 |
| Blueprint Medicines Corporation | 2 | $38 |
| Ionis Pharmaceuticals, Inc. | 2 | $36 |
| Novartis | 2 | $34 |
| Aytu Biopharma, Inc. | 2 | $33 |
| Merck | 2 | $32 |
| Aimmune Therapeutics, Inc. | 2 | $30 |
| Olympus America Inc. | 1 | $30 |
| Galderma Laboratories, L.p. | 2 | $30 |
| Medtronic | 1 | $26 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Incyte Corporation | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
| Glenmark Therapeutics Inc. | 1 | $9 |
How this compares
$5,564 in reported general payments places this provider in the 60th percentile of 135 allergy & immunology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 44 | $174,164 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $20,042 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,445 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,235 |
| Epinephrine | 18 | $5,023 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 35 | $3,862 |
| Azelastine Hcl | 115 | $3,198 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $1,677 |
| Fluticasone Propionate | 94 | $1,520 |
| Ipratropium Bromide | 41 | $811 |
| Epinastine Hcl | 12 | $529 |
| Montelukast Sodium | 76 | $438 |
| Levocetirizine Dihydrochloride | 27 | $298 |
| Triamcinolone Acetonide | 14 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $618 | $27,48742 claims |
| Hikma Pharmaceuticals USAEpinephrine | $47 | $5,02318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 135 allergy & immunology providers in New Jersey.
Other allergy & immunology in Wayne
- Ellen SherOcean$1M
- Peter RickettiTrenton$457K
- John KimMedford$339K
- Tina ZeccaLittle Silver$262K
- George BelecanechVoorhees$208K
- Jacqueline RossOcean$131K
- Shirin JadidiMendham$98K
- Mark WeinsteinBelleville$88K
- Joseph GrizzantiHawthorne$79K
- Lisa BariscianoFlorham Park$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.